Form 4 for BGLC BioNexus Gene Lab Corp
Accepted 2026-08-14 17:18:36 ET · period of report 2026-08-13 · accession 0001520138-26-000347 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 17:18 | 2026-08-13 | BGLC | Bin Abdul Hamid Muhammad Azrul | Dir | A - Grant | — | +32.3K | 32.3K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-08-13 | A | A | 32,258 | — | 32,258 | D | — | — | (F1) Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026). |